Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

BACKGROUND: PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is unclear whether PARPi have similar efficacy in patients with somatic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Mohyuddin, Ghulam Rehman, Aziz, Muhammad, Britt, Alec, Wade, Lee, Sun, Weijing, Baranda, Joaquina, Al-Rajabi, Raed, Saeed, Anwaar, Kasi, Anup
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267765/
https://ncbi.nlm.nih.gov/pubmed/32493233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06948-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados